Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors and Hematological Malignancies”

133 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 133 results

Early research (Phase 1)UnknownNCT04854681
What this trial is testing

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers

Who this might be right for
Advanced Solid Tumors and Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 20
Early research (Phase 1)Looking for participantsNCT06224855
What this trial is testing

DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Who this might be right for
Advanced Solid TumorsHematological Malignancies
Hangzhou DAC Biotechnology Co., Ltd. 110
Early research (Phase 1)Ended earlyNCT02683395
What this trial is testing

PLX51107 in Advanced Malignancies

Who this might be right for
Solid TumorsAcute Myeloid LeukemiaMyelodysplastic Syndrome+1 more
Plexxikon 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439201
What this trial is testing

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+2 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Active Not RecruitingNCT06870487
What this trial is testing

Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Who this might be right for
Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin Lymphoma+3 more
Pfizer 6
Early research (Phase 1)Study completedNCT00046423
What this trial is testing

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Who this might be right for
NeoplasmsMetastases, Neoplasm
Celgene Corporation 20
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Early research (Phase 1)UnknownNCT05549557
What this trial is testing

IMM40H Phase I Dose Escalation and Expansion

Who this might be right for
Tumor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 16
Early research (Phase 1)Active Not RecruitingNCT05104775
What this trial is testing

GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Who this might be right for
Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd. 33
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Early research (Phase 1)UnknownNCT00004036
What this trial is testing

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersDrug/Agent Toxicity by Tissue/OrganLeukemia+5 more
The Cleveland Clinic 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03837899
What this trial is testing

Durvalumab and Tremelimumab for Pediatric Malignancies

Who this might be right for
Pediatric CancerSolid Tumor PediatricHematological Malignancies
AstraZeneca 50
Testing effectiveness (Phase 2)WithdrawnNCT04439305
What this trial is testing

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439123
What this trial is testing

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Looking for participantsNCT05159245
What this trial is testing

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Who this might be right for
Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital 250
Not applicableNot Yet RecruitingNCT04871477
What this trial is testing

Adoption of Audio Recording in the Outpatient Supportive Care Center

Who this might be right for
Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmLocally Advanced Malignant Solid Neoplasm+2 more
M.D. Anderson Cancer Center 200
Large-scale testing (Phase 3)WithdrawnNCT05403580
What this trial is testing

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
Mayo Clinic
Early research (Phase 1)Study completedNCT02367196
What this trial is testing

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

Who this might be right for
Hematologic Neoplasms
Celgene 60
Early research (Phase 1)Looking for participantsNCT06225856
What this trial is testing

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Advanced Solid TumorHematological Malignancy
Shanghai Yuyao Biotech Co., Ltd. 96
Load More Results